{
  "id": "5c6633f27c78d69471000010",
  "type": "summary",
  "question": "What is the mechanism of action of Alpelisib?",
  "ideal_answer": "Alpelisib is selective inhibitor of Phosphatidylinositol 3-Kinase \u03b1 (PI3K\u03b1). It is used for treatment of cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27126994",
    "http://www.ncbi.nlm.nih.gov/pubmed/26793003",
    "http://www.ncbi.nlm.nih.gov/pubmed/30167089",
    "http://www.ncbi.nlm.nih.gov/pubmed/29850984",
    "http://www.ncbi.nlm.nih.gov/pubmed/28852212",
    "http://www.ncbi.nlm.nih.gov/pubmed/29453241",
    "http://www.ncbi.nlm.nih.gov/pubmed/29401002",
    "http://www.ncbi.nlm.nih.gov/pubmed/29563327",
    "http://www.ncbi.nlm.nih.gov/pubmed/29284706",
    "http://www.ncbi.nlm.nih.gov/pubmed/28363909",
    "http://www.ncbi.nlm.nih.gov/pubmed/29789630"
  ],
  "snippets": [
    {
      "text": "The PI3K\u03b1 Inhibitor Alpelisib Has Activity in",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29453241",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The PI3K\u03b1 inhibitor alpelisib achieved a 58.2% disease control rate in PIK3CA-altered solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29453241",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Purpose: We describe herein a novel P447_L455 deletion in the C2 domain of PIK3CA in a patient with an ER+ breast cancer with an excellent response to the PI3K\u03b1 inhibitor alpelisib. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29284706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phosphatidylinositol 3-Kinase \u03b1-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29401002",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Purpose We report the first-in-human phase Ia study to our knowledge ( ClinicalTrials.gov identifier: NCT01219699) identifying the maximum tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase \u03b1 (PI3K\u03b1)-selective inhibitor. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29401002",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we have determined the effects of new anticancer drugs targeting specific PI3K isoforms on INaL and action potentials (APs) in mouse cardiomyocytes and Chinese hamster ovary cells (CHO). Chronic exposure (10-100 nM; 5-48 hours) to PI3K-\u03b1-specific subunit inhibitors BYL710 (alpelisib) and A66 and a pan-PI3K inhibitor (BKM120) increased INaL in SCN5A-transfected CHO cells and mouse cardiomyocytes. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29563327",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Combining ribociclib with the alpha-specific PI3K inhibitor alpelisib showed a synergistic effect in two NPC PDX models in nude mice. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29789630",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "his study aimed to assess the safety and activity of alpelisib (a PI3K\u03b1 isoform-specific inhibitor) with T-DM1 in trastuzumab- and taxane-resistant HER2-positive MBC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29850984",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study aimed to assess the safety and activity of alpelisib (a PI3K\u03b1 isoform-specific inhibitor) with T-DM1 in trastuzumab- and taxane-resistant HER2-positive MBC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29850984",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE\nAlpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110\u03b1, has shown synergistic antitumor activity with endocrine therapy against ER+/PIK3CA-mutated breast cancer cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27126994",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We explored whether PI3K inhibitors, buparlisib and alpelisib, enhance the efficacy of tamoxifen against ER-positive BC cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28852212",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PI3K inhibitors, including the pan-PI3K inhibitor buparlisib (BKM120) and the PI3K\u03b1-selective inhibitor alpelisib (BYL719), currently in clinical development by Novartis Oncology, may therefore be effective as anticancer agents.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26793003",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE Alpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110\u03b1, has shown synergistic antitumor activity with endocrine therapy against ER+/PIK3CA-mutated breast cancer cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27126994",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients with refractory BRAFV600-mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab), with (n = 28) or without (n = 26) a PI3K\u03b1 inhibitor (alpelisib).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28363909",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Combining ribociclib with the alpha-specific PI3K inhibitor alpelisib showed a synergistic effect in two NPC PDX models in nude mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29789630",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We assessed the safety and activity of alpelisib, an oral, selective PI3K p110\u03b1 inhibitor, plus paclitaxel in patients with advanced solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30167089",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study aimed to assess the safety and activity of alpelisib (a PI3K\u03b1 isoform-specific inhibitor) with T-DM1 in trastuzumab- and taxane-resistant HER2-positive MBC.<br><b>METHODS</b>: Patients with HER2-positive MBC that had progressed on trastuzumab-based therapy were treated with alpelisib daily and T-DM1 3.6\u00a0mg/kg every 3 weeks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29850984",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}